KALY - PAOG to soon finalize CRO engagement for Cannabis drug

PAO Group ([[PAOG]] +10.5%) anticipates entering into an agreement with a contract research organization or CRO within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (or COPD) toward FDA approval.PAOG acquired RespRx from Kali-Extracts ([[KALY]] -8.3%), which is a cannabis treatment under development for COPD derived from a patented cannabis extraction method.Related: PURA in management takeover deal with PAO Group.Press Release

For further details see:

PAOG to soon finalize CRO engagement for Cannabis drug